Invex Therapeutics Limited
- Biotech or pharma, therapeutic R&D
Invex Therapeutics (Invex) is an Australian Securities Exchange (ASX)-listed biopharmaceutical company (ASX:IXC) focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP).
Invex is seeking partners to acquire the Company’s core IP related to raised ICP in neurological disorders based on GLP-1RAs, including Exenatide. The Company’s research priorities have changed and Invex is seeking to divest its core IP assets in exchange for cash, equity or some combination thereof.
The Company maintains a cash position of approximately $6 million, with the ability to leverage new funds or equity for new pipeline opportunities by way of asset or company acquisitions or in-licensing, preferably within the neuroscience or orphan disease space.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}